NanoMed Pharmaceuticals Founders Issued Patent for Use of Nanoparticles to Detect Radioisotopes

'NanoScintillation Systems(TM)' Detect Carbon-14 Without the Use of Organic

Solvents; Nanoparticle-Based System Would Reduce Hazardous Environmental Waste

Nov 29, 2005, 00:00 ET from NanoMed Pharmaceuticals, Inc.

    LEXINGTON, Ky. and KALAMAZOO, Mich., Nov. 29 /PRNewswire/ -- NanoMed
 Pharmaceuticals, Inc. founders Michael Jay, Ph.D. and Russell J. Mumper, Ph.D.
 have been issued U.S. Patent 6,855,270 entitled "NanoScintillation Systems For
 Aqueous-Based Liquid Scintillation Counting." Their invention, assigned to the
 University of Kentucky Research Foundation and licensed exclusively to NanoMed
 Pharmaceuticals, covers processes to make nanoparticle-based NanoScintillation
 Systems which are used to detect beta-particle- or alpha-particle-emitting
 radioisotopes without the use of the organic solvents commonly used in
 conventional liquid scintillation (LS) "cocktails."
     Biomedical and environmental researchers routinely employ scintillation
 cocktails to quantify, or "count," the amount of radioactivity emitted by
 radioisotopes in samples generated during laboratory experiments. Frequently,
 these samples must be mixed with an organic solvent containing dissolved fluor
 molecules, or "scintillators." Although efficient, the use of organic-based LS
 cocktails results in the need to dispose of large quantities of mixed low-
 level radioactive and hazardous waste ("Mixed LLW") generated as a byproduct
 of the counting process. Results of testing by TestAmerica, Inc.,
 ( ), the leading nationally certified provider
 of outsourced analytical laboratory, air emissions, and indoor air quality
 testing services, show that the NanoScintillation System was qualified as non-
 hazardous waste by virtue of passing tests for Toxicity Characteristic
 Leaching Procedure (TCLP) Extraction by EPA 1311, TCLP for Volatile Organic
 Compounds by EPA Method 1311/8260B, TCLP for Semi-volatile Organic Compounds
 by EPA Method 1311/8270C, TCLP for Metals by 6000/7000 Series Methods,
 Reactivity, pH, and Ignitability as specified in Subpart C of 40 CFR Part 261.
 Thus, the NanoScintillation System represents an opportunity to significantly
 reduce hazardous environmental waste.
     "With the advent of nanotechnology, methods now exist to enhance the
 aqueous solubility of fluor molecules without the use of organic solvents,"
 said Michael Jay, Ph.D., NanoMed co-founder and Director of the University of
 Kentucky's Center for Pharmaceutical Science & Technology. "The development of
 NanoScintillation Systems provides the potential for tremendous scientific,
 economic, and environmental advantages, most notably the opportunity to
 greatly reduce the amount of mixed radioactive and hazardous waste generated
 through the widespread use of conventional organic-based LS cocktails," Dr.
 Jay added.
     Background and Significance
     According to a 1990 baseline report commissioned by the Nuclear Regulatory
 Commission and the Environment Protection Agency titled "National Profile on
 Commercially Generated Low-Level Radioactive Mixed Waste" (NUREG/CR-5938),
 140,000 cubic feet of mixed waste was generated by industry and academia in
 the United States in 1990 alone. It is estimated that the Department of Energy
 generates annually an additional 800,000 cubic feet of mixed organic and
 radioactive waste.
     Additional Potential Applications
     In addition to its application in routine scintillation counting in
 biomedical and pharmaceutical research laboratories, NanoScintillation Systems
 may have utility in homeland security applications; specifically, anti-nuclear
 terrorism of municipal and military water supplies. Several U.S. government
 agencies have made nuclear preparedness recommendations that included the use
 of mobile methods to detect radiation, including beta-particle- or alpha-
 particle-emitting radioisotopes.
     NanoScintillation Systems may also have applications in other areas such
 as in radioisotopic binding assays and in functional genomics whereby the
 binding of radiolabeled probes in DNA microarrays can be quantified which may
 be of particular interest to biomedical researchers who build their own gene
 chips and need high sensitivity detection.
     About the Inventors
     Michael Jay, Ph.D. is Professor in the University of Kentucky Department
 of Pharmaceutical Sciences with a joint appointment in the Department of
 Diagnostic Radiology of the Chandler Medical Center, and Director of the
 University of Kentucky's Center for Pharmaceutical Science and Technology.
     Russell J. Mumper, Ph.D. is Vice Chair and Associate Professor in the
 University of Kentucky, College of Pharmacy, Department of Pharmaceutical
 Sciences, and Associate Director of the University of Kentucky's Center for
 Pharmaceutical Science & Technology
     About NanoMed Pharmaceuticals, Inc.
     NanoMed Pharmaceuticals, Inc. is an advanced drug delivery systems company
 developing therapeutic and diagnostic products to treat or detect disease.
 The Company's initial focus is cancer therapeutics and diagnostics. NanoMed's
 core technology is Nanotemplate Engineering(TM), a flexible, rapid and
 scaleable nanoparticle manufacturing technology for the delivery of small
 molecules, peptides, proteins, plasmid DNA, and diagnostic agents.

SOURCE NanoMed Pharmaceuticals, Inc.